Edition:
United Kingdom

Biocept Inc (BIOC.OQ)

BIOC.OQ on NASDAQ Stock Exchange Capital Market

0.70USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
85,531
52-wk High
$3.38
52-wk Low
$0.60

Chart for

About

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally... (more)

Overall

Beta: 3.04
Market Cap(Mil.): $39.03
Shares Outstanding(Mil.): 30.25
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.16 16.44
EPS (TTM): -- -- --
ROI: -- 14.01 10.62
ROE: -- 16.85 14.20

BRIEF-Sabby Management LLC Reports A 9.20 Pct Passive Stake In Biocept

* SABBY MANAGEMENT LLC REPORTS A 9.20 PCT PASSIVE STAKE IN BIOCEPT INC AS OF DEC 5 - SEC FILING Source text: (http://bit.ly/2ACbgue) Further company coverage:

06 Dec 2017

BRIEF-Biocept announces pricing of public offering of up to 4,925,936 shares of common stock

* BIOCEPT ANNOUNCES PRICING OF PUBLIC OFFERING OF UP TO 4,925,936 SHARES OF COMMON STOCK

06 Dec 2017

BRIEF-Biocept And UC San Diego Medical Center Announce Clinical Study Collaboration To Demonstrate Utility Of Biocept's Liquid Biopsy Test In Immunotherapy

* BIOCEPT AND UC SAN DIEGO MEDICAL CENTER ANNOUNCE CLINICAL STUDY COLLABORATION TO DEMONSTRATE UTILITY OF BIOCEPT'S LIQUID BIOPSY TEST IN IMMUNOTHERAPY Source text for Eikon: Further company coverage:

28 Nov 2017

BRIEF-Biocept files for offering $10 mln of shares of co's common stock and warrants

* Biocept Inc files for offering $10 million of shares of co's common stock and warrants - SEC Filing

17 Nov 2017

BRIEF-Biocept reports Q3 loss per share $0.20

* Biocept Inc - ‍cash and cash equivalents were $5.9 million as of September 30, 2017​ Source text for Eikon: Further company coverage:

09 Nov 2017

BRIEF-Biocept and Miraca Life Sciences enter into marketing agreement

* Biocept and Miraca Life Sciences enter into marketing agreement to expand target selector testing in the United States

03 Oct 2017

BRIEF-Biocept Inc files for disposition of up to 2.9 million shares of common stock

* Biocept Inc files for disposition of up to 2.9 million shares of common stock by the selling stockholders Source text: (http://bit.ly/2fShoIH) Further company coverage:

18 Aug 2017

BRIEF-Biocept, UT Southwestern Medical Center announce clinical study to profile, monitor non-small cell lung cancer patients

* Biocept and UT Southwestern medical center announce clinical study to profile and monitor non-small cell lung cancer patients with ALK rearrangements Source text for Eikon: Further company coverage:

17 Aug 2017

BRIEF-Biocept enters into distribution agreement with Global Laboratory Product Supplier VWR

* Biocept enters into exclusive distribution agreement with Global Laboratory Product Supplier VWR

14 Aug 2017

BRIEF-Biocept Q2 loss per share $0.21

* Says ‍revenues for Q2 of 2017 increased 93% to $1.3 million​

10 Aug 2017

Earnings vs. Estimates